Primaquine: The Definitive Antimalarial for Radical Cure and Relapse Prevention
| Product dosage: 15 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.89 | $56.76 (0%) | 🛒 Add to cart |
| 60 | $1.43 | $113.52 $86.00 (24%) | 🛒 Add to cart |
| 90 | $1.28 | $170.28 $115.24 (32%) | 🛒 Add to cart |
| 120 | $1.12 | $227.04 $134.16 (41%) | 🛒 Add to cart |
| 180 | $1.04
Best per pill | $340.56 $187.48 (45%) | 🛒 Add to cart |
| Product dosage: 7.5 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.61 | $48.16 (0%) | 🛒 Add to cart |
| 60 | $1.43 | $96.32 $86.00 (11%) | 🛒 Add to cart |
| 120 | $1.34 | $192.64 $160.82 (17%) | 🛒 Add to cart |
| 270 | $1.15 | $433.44 $311.32 (28%) | 🛒 Add to cart |
| 360 | $1.07
Best per pill | $577.92 $386.14 (33%) | 🛒 Add to cart |
Primaquine phosphate is an 8-aminoquinoline antimalarial agent with a distinct and critical role in modern parasitology. It is not a first-line treatment for acute malaria attacks but is indispensable for achieving a radical cure, primarily for infections caused by Plasmodium vivax and Plasmodium ovale. Its unique mechanism of action targets the dormant hypnozoite forms of these parasites residing in the liver, which are responsible for relapsing malaria. This makes primaquine the cornerstone of efforts to prevent malaria recurrence and a vital tool for malaria eradication programs. Its use requires expert medical supervision due to specific and serious safety considerations.
Features
- Active Ingredient: Primaquine phosphate.
- Drug Class: 8-Aminoqunoline antimalarial.
- Available Forms: Oral tablets (typically 7.5 mg and 15 mg of the base).
- Mechanism of Action: Generates reactive oxygen species that are toxic to plasmodia; specifically targets the exo-erythrocytic (liver) stages, including hypnozoites.
- Prescription Status: Available by prescription only in most jurisdictions.
Benefits
- Achieves Radical Cure: Eradicates the dormant liver-stage hypnozoites of P. vivax and P. ovale, preventing future relapses of malaria.
- Gametocytocidal Action: Effectively kills gametocytes of Plasmodium falciparum, reducing transmissibility and helping to interrupt the chain of malaria transmission in communities.
- Prophylactic Utility: Used as primary prophylaxis or terminal prophylaxis (for presumptive anti-relapse therapy) in individuals with significant exposure to P. vivax.
- Critical for Eradication Efforts: Plays a pivotal role in public health strategies aimed at malaria control and eventual elimination by addressing the reservoir of infection that drives transmission.
Common use
Primaquine’s primary indication is for the radical cure (anti-relapse therapy) of malaria caused by Plasmodium vivax and Plasmodium ovale. It is always administered following a course of a blood schizonticide (e.g., chloroquine or artemisinin-based combination therapy) that clears the acute, symptomatic blood-stage infection. It is also used for terminal prophylaxis in individuals leaving an area with endemic P. vivax. Furthermore, a single low dose is recommended by the WHO to block transmission of Plasmodium falciparum malaria in control programs, as it effectively eliminates gametocytes.
Dosage and direction
Dosing is weight-based and must be calculated precisely as milligrams of primaquine base. A crucial prerequisite is testing for Glucose-6-Phosphate Dehydrogenase (G6PD) enzyme deficiency before initiation.
- Radical Cure for P. vivax malaria: The standard adult dose is 30 mg base (0.5 mg base/kg) orally once daily for 14 days, taken with food to minimize gastrointestinal upset. This follows initial treatment with chloroquine or other appropriate blood-stage therapy.
- Terminal Prophylaxis: 30 mg base daily for 14 days after leaving the endemic area.
- Single Low Dose for P. falciparum transmission blocking: 0.25 mg base/kg as a single dose, co-administered with a primary treatment for acute falciparum malaria.
Direction: Take exactly as prescribed by your physician. Do not stop the course early, even if you feel better, as this increases the risk of relapse. Complete the full 14-day course.
Precautions
- G6PD Testing is Mandatory: Primaquine can cause severe hemolysis (destruction of red blood cells) in individuals with G6PD deficiency. Quantitative testing must be performed prior to prescription. Use is contraindicated in patients with severe deficiency and requires specialized dosing and monitoring in those with mild to moderate deficiency.
- Pregnancy: Generally contraindicated during pregnancy due to the unknown G6PD status of the fetus and risk of fetal hemolysis. Use only if the potential benefit justifies the potential risk to the fetus.
- Lactation: Should generally be avoided in breastfeeding women unless the infant has been tested and confirmed to have normal G6PD levels.
- Nicotinamide Adenine Dinucleotide (NADH) Methemoglobin Reductase Deficiency: Can exacerbate drug-induced methemoglobinemia.
- Monitoring: Patients should be monitored for signs of hemolysis (dark urine, jaundice, severe fatigue, shortness of breath) and methemoglobinemia (cyanosis).
Contraindications
- Known G6PD deficiency (absolute contraindication for standard dosing).
- Pregnancy (due to risk to the fetus).
- Concurrent administration with other drugs known to cause hemolysis or depress the myeloid series of the bone marrow.
- Patients with conditions exhibiting a tendency to granulocytopenia (e.g., rheumatoid arthritis, lupus erythematosus).
- Known hypersensitivity to primaquine or any component of the formulation.
Possible side effect
- Common: Abdominal cramps, nausea, vomiting, epigastric distress, chest pain.
- Serious (Require immediate medical attention):
- Hemolytic Anemia: Especially in G6PD-deficient individuals, presenting as dark urine, yellowing of skin/eyes (jaundice), severe tiredness, shortness of breath, rapid heart rate.
- Methemoglobinemia: Bluish coloration of the skin, lips, or nail beds (cyanosis), headache, fatigue, shortness of breath, confusion.
- Leukopenia: Uncommon, but a decrease in white blood cell count can occur.
- Cardiac Arrhythmias: Rare.
Drug interaction
- Other Hemolytic Drugs: Concurrent use with drugs like sulfonamides, nitrofurantoin, dapsone, or quinine may increase the risk of hemolytic reactions.
- Myelosuppressive Agents: May compound the bone marrow suppression effects of other drugs.
- Drugs that cause methemoglobinemia: e.g., Nitrates, nitrites, local anesthetics (benzocaine, lidocaine), dapsone. Concurrent use increases the risk of clinically significant methemoglobinemia.
Missed dose
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the next dose at the regular time. Do not take a double dose to make up for a missed one. Inform your healthcare provider of any missed doses.
Overdose
Symptoms of overdose are an exaggeration of the known adverse effects, particularly severe abdominal cramps, vomiting, burning epigastric distress, central nervous and cardiovascular disturbances, cyanosis, methemoglobinemia, hemolytic anemia, and granulocytopenia. Primaquine overdose is a medical emergency. Seek immediate medical attention or contact a Poison Control Center. Treatment is supportive and may include methylene blue for significant methemoglobinemia.
Storage
Store at room temperature (20°C to 25°C or 68°F to 77°F) in a tight, light-resistant container. Keep out of reach of children and pets. Do not flush medications down the toilet or pour them into a drain unless instructed to do so.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The author and publisher are not responsible for any errors or omissions or for any outcomes related to the use of this information.
Reviews
- “As an infectious disease specialist working in Southeast Asia, primaquine is an irreplaceable part of our arsenal against vivax malaria. The 14-day course is a compliance challenge, but its efficacy in preventing relapse is unmatched. The mandatory G6PD screening protocol is non-negotiable for safe use.” – Dr. A. Sharma, MD
- “From a public health perspective, the implementation of single low-dose primaquine for falciparum gametocyte clearance has been a game-changer in our regional elimination efforts. It’s a powerful tool for reducing transmission.” – Public Health Official, Sub-Saharan Africa
- “The patient education component is critical. We spend considerable time explaining the importance of completing the full course and the specific signs of hemolysis to watch for. When managed correctly, it is a highly effective and well-tolerated therapy.” – Clinical Pharmacist